Journal of Medicinal Chemistry
ARTICLE
G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.; McInnes, C.; Zheleva, D.;
Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine
CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and
Biological Activity. J. Med. Chem. 2004, 47, 1662–1675. (b) Ibrahim,
D. A.; EI-Metwally, A. M. Design, synthesis, and biological evaluation of
novel pyrimidine derivatives as CDK2 inhibitors. Eur. J. Med. Chem.
2010, 45, 1158–1166.
(2) Brugel, T. A.; Maier, J. A.; Clark, M. P.; Sabat, M.; Golebiowski,
A.; Bookland, R. G.; Laufersweiler, M. J.; Laughlin, S. K.; VanRens, J. C.;
De, B.; Hsieh, L. C.; Mekel, M. J.; Janusz, M. J. Development of N-2,4-
pyrimidine-N-phenyl-N0-phenyl ureas as inhibitors of tumor necrosis
factor alpha (TNF-R) synthesis. Part 1. Bioorg. Med. Chem. Lett. 2006,
16, 3510–3513.
(3) Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon,
N. B. Potent and Selective Inhibitors of the ABL-kinase: Phenylamino-
pyrimidine(PAP) Derivertives. Bioorg. Med. Chem. Lett. 1997, 7, 187–192.
(4) (a) Bailey, J. P.; Giles, M. B.; Pass, M. 2,4,6-Trisubstituted
Pyrimidines as Phosphotidylinositol(PI) 3-kinase Inhibitors and Their
Use in the Treatment of Cancer. WO 2006005914 A1, 2006. (b) Pecchi,
S.; Renhowe, P. A.; Taylor, C.; Kaufman, S.; Merritt, H.; Weismann, M.;
Shoemaker, K. R.; Knapp, M. S.; Ornelas, E.; Hendrickson, T. F.; Fantl,
W.; Voliva, C. F. Identification and structure-activity relationship of
2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and
selective PI3 kinase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20,
6895–6898.
(5) Bilodeau, M. T.; Chua, P. C.; Cosford, N. D. P.; Hoffman, J. M.;
Nagasawa, J. Inhibitors of AKT Activity. WO 2005100344 A1, 2005.
(6) Srinivas, A. S. S. V.; Tadiparthi, R.; Sharma, G. V. R.;
Thirunavukkarasu, S.; Bhakiaraj, D. P.; Kachhadia, V.; Narsimhan, K.;
Thara, S. N.; Rajagopal, S.; Reddy, G.; Narayanan, S.; Parameswaran, V.;
Janarthanam, V.; Narayanam, M.; Gadde, S.; Ramachandran, U. Novel
Heterocycles. US 20080207606 A1, 2008.
Synthesis, Antiproliferative Activity, and Inhibition of Tubulin Poly-
merization. J. Med. Chem. 2009, 52 (5), 1284–1294.
(18) (a) Nien, C. Y.; Chen, Y. C.; Kuo, C. C.; Hsieh, H. P.; Chang,
C. Y.; Wu, J. S.; Wu, S. Y.; Liou, J. P.; Chang, J. Y. 5-Amino-2-
Aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors.
J. Med. Chem. 2010, 53, 2309–2313. (b) Lee, J.; Kim, S. J.; Choi, H.; Kim,
Y. H.; Lim, I. T.; Yang, H.; Lee, C. S.; Kang, H. R.; Ahn, S. K.; Moon,
S. K.; Kim, D. H.; Lee, S.; Choi, N. S.; Lee, K. J. Identification of CKD-
516:A Potent Tubulin Polymerization Inhibtitor with Marked Antitu-
mor Activity against Murine and Human Solid Tumors. J. Med. Chem.
2010, 53, 6337–6354. (c) Chen, J.; Wang, Z.; Li, C.-M.; Lu, Y.; Vaddady,
P. K.; Meibohm, B.; Dalton, J. T.; Miller, D. D.; Li, W. Discovery of
Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding
Site in Tubulin As Potential Anticancer Agents. J. Med. Chem. 2010,
53, 7414–7427. (d) O'Boyle, N. M.; Carr, M.; Greene, L. M.; Bergin, O.;
Nathwani, S. M.; McCabe, T.; Lloyd, D. G.; Zisterer, D. M.; Meegan,
M. J. Synthesis and Evaluation of Azetidinone Analogues of Combre-
tastatin A-4 as Tubulin Targeting Agents. J. Med. Chem. 2010,
53, 8569–8584. (e) Arthuis, M.; Pontikis, R.; Chabot, G. G.; Quentin,
L.; Scherman, D.; Florent, J. C. Domino approach to 2-aroyltrimethox-
yindoles as novel heterocyclic combretastatin A4 analogues. Eur. J. Med.
Chem. 2011, 46, 95–100. (f) Regina, G. L.; Edler, M. C.; Brancale, A.;
Kandil, S.; Coluccia, A.; Piscitelli, F.; Hamel, E.; Martino, G. D.;
Matesanz, R.; Díaz, J. F.; Scovassi, A. I.; Prosperi, E.; Lavecchia, A.;
Novellino, E.; Artico, M.; Silvestri, R. Arylthioindole Inhibitors of
Tubulin Polymerization. 3. Biological Evaluation, Structure-Activity
Relationships and Molecular Modeling Studies. J. Med. Chem. 2007,
50, 2865–2874. (g) Duan, J.-X.; Cai, X.; Meng, F.; Lan, L.; Hart, C.;
Matteucci, M. Potent Antitubulin Tumor Cell Cytotoxins Based on
3-Aroyl Indazoles. J. Med. Chem. 2007, 50, 1001–1006. (h) Zhang, Q.;
Peng, Y.; Wang, X. I.; Keenan, S. M.; Arora, S.; Welsh, W. J. Highly
Potent Triazole-Based Tubulin Polymerization Inhibitors. J. Med. Chem.
2007, 50, 749–754. (i) Romagnoli, R.; Baraldi, P. G.; Sarkar, T.; Carrion,
M. D.; Lopez Cara, C.; Lopez, O. C.; Preti, D.; Tabrizi, M. A.; Tolomeo,
M.; Grimaudo, S.; Di Antonella, C.; Zonta, N.; Balzarini, J.; Brancale, A.;
Hsieh, H.-P.; Hamel, E. Synthesis and Biological Evaluation of 1-Methyl-
2-(30,40,50-trimethoxybenzoyl)-3-aminoindoles as a New Class of Anti-
mitotic Agents and Tubulin Inhibitors. J. Med. Chem. 2008,
51, 1464–1468.
(7) Xie, F.; Zhao, H.; Zhao, L.; Lou, L.; Hu, Y. Synthesis and
biological evaluation of novel 2,4,5-substituted pyrimidine derivatives
for anticancer activity. Bioorg. Med. Chem. Lett. 2009, 19, 275–278.
(8) Tahir, S. K.; Trogadis, J. E.; Stevens, J. K.; Zimmerman, A. M.
Cytoskeletal organization following cannabinoid treatment in undiffer-
entiated and differentiated PC12 cells. Biochem. Cell Biol. 1992, 70,
1159–1173.
(9) Wilson, R. G.; Tahir, S. K.; Mechoulam, R.; Zimmerman, S.;
Zimmerman, A. M. Cannabinoid enantiomer action on the cytoarchi-
tecture. Cell Biol. Int. 1996, 20, 147–157.
(10) Hamel, E. Antimitotic natural products and their interactions
with tubulin. Med. Res. Rev. 1996, 16, 207–231.
(11) Jordan, M. A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T.
Tubulin as a target for anticancer drugs: Agents which interact with the
mitotic spindle. Med. Res. Rev. 1998, 18, 259–296.
(19) Xie, F.; Li, S.; Bai, D.; Lou, L.; Hu, Y. Three-Component One-
Pot Synthesis of 2,4,5-Substituted Pyrimidines Library for Screening
against Human Hepatocellular Carcinoma BEL-7402 Cells. J. Comb.
Chem. 2007, 9, 12–13.
(20) Shelanski, M. L.; Gaskin, F.; Cantor, C. R. Microtubule
assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci.
U.S.A. 1973, 70, 765–768.
(21) Tong, Y. G. Pseudolarix Acid B, a New Tubulin-Binding Agent,
Inhibits Angiogenesis by Interacting with a Novel Binding Site on
Tubulin. Mol. Pharmacol. 2006, 69, 1226–1233.
(12) Rai, S. S.; Wolff, J. Localization of the vinblastine-binding site
on β-tubulin. J. Biol. Chem. 1996, 271, 14707–14711.
(13) Zuse, A.; Schmidt, P.; Baasner, S.; B€ohm, K. J.; M€uller, K.;
Gerlach, M.; G€unther, E. G.; Unger, E.; Prinz, H. Sulfonate Derivatives
of Naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-Anthracenone as
Highly Active Antimicrotubule Agents. Synthesis, Antiproliferative
Activity, and Inhibition of Tubulin Polymerization. J. Med. Chem.
2007, 50, 6059–6066.
(22) Herzog, W.; Weber, K. In vitro assembly of pure tubulin into
microtubules in the absence of microtubule-associated proteins and
glycerol. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 1860–1864.
(14) Kingston, D. G. I. Tubulin-Interactive Natural Products as
Anticancer Agents(1). J. Nat. Prod. 2009, 72, 507–515.
(15) Fox, E.; Maris, J. M.; Widemann, B. C.; Goodspeed, W.;
Goodwin, A.; Kromplewski, M.; Fouts, M. E.; Medina, D.; Cohn,
S. L.; Krivoshik, A.; Hagey, A. E.; Adamson, P. C.; Balis, F. M. A Phase
I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Adminis-
tered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid
Tumors. Clin. Cancer Res. 2008, 14, 1111–1115.
(16) Chen, S.-M.; Meng, L.-H.; Ding, J. New microtubule-inhibiting
anticancer agents. Expert Opin. Invest. Drugs 2010, 19 (3), 329–343.
(17) Prinz, H.; Schmidt, P.; B€ohm, K. J.; Baasner, S.; M€uller, K.;
Unger, E.; Gerlach, M.; G€unther, E. G. 10-(2-oxo-2-Phenylethylidene)-
10H-anthracen-9-ones as Highly Active Antimicrotubule Agents:
3205
dx.doi.org/10.1021/jm101388d |J. Med. Chem. 2011, 54, 3200–3205